Differential Expression of Programmed Death-1 (PD-1) in Sézary Syndrome and Mycosis Fungoides

Çetinözman, Fatma; Jansen, Patty M.; Vermeer, Maarten H.; Willemze, Rein

doi:10.1001/archdermatol.2012.2089

Cited by 116 publications

(100 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cutaneous proliferations of T cells may express markers of TFH cells. Accordingly, PD-1 is expressed by the tumor cells of patients with Sézary syndrome [73], primary cutaneous CD4+ small/medium T-cell lymphoma [74], and a rare type of CD4/CD8 double-negative mycosis fungoides [75]. Additionally, PD-L1 is overexpressed by anaplastic lymphoma kinase positive (ALK + ) anaplastic large cell lymphoma cells in a chimeric nucleophosmin/ALK-STAT3–dependent manner [76].…”

Section: Expression and Clinical Significance Of Pd-1 And Its Ligamentioning

confidence: 99%

Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies

Xia

Medeiros

Young

2016

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

Tumor cells evade immune destruction, at least partially, by upregulating inhibitory signals to limit effector T cell activation. Programmed death 1 (PD-1) is one of the most critical co-inhibitory molecules limiting the T-cell antitumor response. PD-1 and its ligands, PD-L1 and PD-L2, are overexpressed by various types of tumors as well as reactive cells in the tumor microenvironment. A growing body of evidence has shown the clinical efficiency and minimal toxicity of PD-1 pathway inhibitors in patients with solid tumors, but the role of these inhibitors in lymphoid malignancies is much less well studied. In this review, we review the pathologic role of the PD-1 pathway in most common lymphoid malignancies and we organize the clinical data from clinical trials of PD-1 pathway inhibitors. Several anti–PD-1 regimens have shown encouraging therapeutic effects in patients with relapsed/refractory Hodgkin lymphoma, follicular lymphoma, and diffuse large B cell lymphoma. Additional progress is needed to foster an improved understanding of the role of anti–PD-1 therapy in reconstituting antitumor immunity in patients with lymphoid malignancies. Upcoming trials will explore the clinical efficiency of combining PD-1 pathway inhibitors and various agents with diverse mechanisms of action and create more therapeutic possibilities for afflicted patients.

show abstract

Section: Expression and Clinical Significance Of Pd-1 And Its Ligamentioning

confidence: 99%

Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies

Xia

Medeiros

Young

2016

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

show abstract

“…Further supporting the notion that MF and SS are distinct despite some common clinical features, SS exhibits a phenotype consistent with central memory T-cells, with expression of CCR7, Lselectin, and CD27, while MF lacks significant expression of these molecules and exhibits a skin resident effector memory T-cell immunophenotype [69]. In addition, PD-1 expression is common in SS, while it is fairly rare in MF [70].…”

Section: Clinical Featuresmentioning

confidence: 58%

Mature T-cell leukemias: Molecular and Clinical Aspects

Bailey

Elenitoba-Johnson

2015

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Mature T-cell leukemias are a group of uncommon lymphoid neoplasms. These disorders have widely variable clinical features, ranging from indolent, slowly progressive processes to diseases with rapidly progressive courses, leading to death. Cytogenetic aberrations have long been identified in some of these diseases, and recent studies have found recurrent genetic mutations that contribute to their pathogenesis. Conventional multiagent chemotherapy lacks significant efficacy in this group of diseases and therapies vary from immunosuppression to treatment with monoclonal antibodies, antiviral agents, and hematopoietic stem cell transplantation. The recent expansion of knowledge regarding the underlying genetic basis of these disorders raises hope that new, more targeted therapeutic approaches will be available to patients in the near future.

show abstract

“…According to recent publications, the absence of a significant expression of PD1 and CXCL13 in MF was expected. 27,28 Finally, in our opinion, the B-cell component observed in the skin of our patients being more the result of a homing process than a true cutaneous localization of the B-cell malignant disease, our cases should much more be considered as discordant cutaneous lymphomas than as composite lymphomas. To conclude, both folliculotropic MF and pseudo-folliculotropic MF may occur in patients with small B-cell lymphoproliferations, especially B-CLL.…”

Section: Discussionmentioning

confidence: 69%

Folliculotropic T‐cell infiltrates associated with B‐cell chronic lymphocytic leukaemia or MALT lymphoma may reveal either true mycosis fungoides or pseudolymphomatous reaction: seven cases and review of the literature

Ingen‐Housz‐Oro¹,

Franck

Bénéton

et al. 2014

Acad Dermatol Venereol

View full text Add to dashboard Cite

Folliculotropic T-cell infiltrates associated with B-cell malignancies can be either a true folliculotropic MF or a pseudo-MF. The distinction between both conditions cannot rely only on the histopathological aspect, but needs both a clinical pathological correlation and the search for a dominant T-cell clone. Whether the neoplastic T and B cells derive from a common ancestor or the T-cell proliferation is promoted by the underlying B-cell lymphoma remains unsolved, but interaction between B and T cell in the skin does not appear to be dependent on a TFH differentiation of the T-cell infiltrate.

show abstract

Differential Expression of Programmed Death-1 (PD-1) in Sézary Syndrome and Mycosis Fungoides

Cited by 116 publications

References 30 publications

Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies

Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies

Mature T-cell leukemias: Molecular and Clinical Aspects

Folliculotropic T‐cell infiltrates associated with B‐cell chronic lymphocytic leukaemia or MALT lymphoma may reveal either true mycosis fungoides or pseudolymphomatous reaction: seven cases and review of the literature

Contact Info

Product

Resources

About